Drug Discovery World

MARCH 13, 2023

The cell and gene therapy (CGT) landscape has grown significantly in the past year. Between the 24 therapies already approved by the FDA 1 and a marked increase in clinical trials, widespread accessibility to precision medicine feels within reach. But now, the increased efficiency is likely making drug development cheaper.

Gene Therapy 52

Gene Therapy Gene Manufacturing Development 52

Pharmaceutical Technology

FEBRUARY 3, 2023

With scientists fervently developing mRNA vaccines, nucleic acid therapeutics, and viral vector-based gene therapies, clinicians are set to have a growing number of tools available to treat a wide range of conditions, from infectious diseases to genetic disorders and more.

Genome 244

Genome Genomics Medicine Gene Therapy 244

Roots Analysis

APRIL 5, 2023

In fact, non-viral vectors are significantly less expensive than their virus-based counterparts, implying the potential for use in the development of more affordable gene therapies. Currently, highest number of patent for non-viral transfection reagents and systems is filed in North America region.

Reagent 52

Reagent Marketing Gene Therapy Gene 52

Drug Discovery World

JANUARY 19, 2023

This paid-for advertorial by Catalent appeared in DDW Volume 24 – Issue 1, Winter 2022/2023 One significant challenge in the manufacturing of cell and gene therapies is the production of high-quality plasmid DNA (pDNA). Figure 1: The integrated development pathway for cell and gene therapies.

DNA 52

DNA Manufacturing Gene Therapy Gene 52

Drug Discovery World

AUGUST 11, 2023

The news headlines this week reflect the level of interest in cell & gene therapies (CGT) in the sector, particularly CAR-T, but also the importance of research collaborations to bring these therapies to patients. News round-up for by DDW Digital Content Editor Diana Spencer.

Gene Therapy 52

Gene Therapy Drugs Clinical Trials Clinical Trials 52

The Pharma Data

MAY 17, 2021

Academic centers should establish risk management programs to successfully commercialize cell and gene therapy products and to be a viable partner with contract research organizations (CROs) and manufacturers in developing these therapies. . Posted 17 May 2021 | By Joanne S. Eglovitch . Historical origins. .

Development 52

Development Gene Therapy Manufacturing Gene 52

FDA Law Blog

JANUARY 4, 2023

The purpose of these town halls are to discuss topics related to OTAT-regulated products, engage with product development stakeholders, and to provide information to help stakeholders to help advance drug development. The next town hall will focus on the clinical development of gene therapy products for rare diseases in February 2023.

Reagent 59

Reagent Manufacturing Production Gene Therapy 59

Drug Discovery World

JANUARY 30, 2024

Viral vector manufacturing At the Advanced Therapies Awards ceremony, Dr Luigi Naldini, Director of the San Raffaele Telethon Institute for Gene Therapy, was awarded a Lifetime Achievement Award in recognition of ‘extraordinary contributions to gene therapy’, a field he has helped shape through his pioneering work on lentiviral vectors.

Gene Therapy 71

Gene Therapy Manufacturing Gene Clinical Trials 71

Roots Analysis

JUNE 1, 2022

Many diseases that can be treated using DNA cloning, such as leukemia and sickle cell anemia, involving the replacement of defected gene. The pandemic has specifically resulted in enhanced research and development activities in the field of biotechnology. DNA Cloning Reagent Providers – Current Market Landscape.

DNA 52

DNA Genetics Reagent Marketing 52

Drug Discovery World

MARCH 27, 2023

Download this new white paper ‘Diving deep into cell therapy: An industry perspective’ to find out more. The post New whitepaper: Take a deep dive into cell therapy appeared first on Drug Discovery World (DDW).

Reagent 52

Reagent Manufacturing Development Research 52

Drug Discovery World

FEBRUARY 8, 2023

Svea Cheeseman , Refeyn, explains why better efficiency is needed to advance the production of viral vectors for use in gene therapies. Adeno-associated viruses (AAVs) are a promising, widely used vector for delivering gene therapies. What makes an ideal AAV analytics tool for process development?

Gene Therapy 52

Gene Therapy Gene Antibody Production 52

Drug Discovery World

MARCH 27, 2023

Cell therapy research has never been more exciting with all of the research ongoing.

Reagent 52

Reagent Manufacturing Development Drugs 52

Drug Discovery World

APRIL 3, 2023

I quickly recognised the commercial value of aptamers as being able to address the gap in the market where antibodies fail to perform, and together we established the business to begin aptamer development. DS: How are aptamers currently used in the development of precision treatments? DS: The company now has clients across big pharma.

Antibody 52

Antibody Gene Therapy Gene In-Vitro 52

pharmaphorum

DECEMBER 16, 2022

Dopavision, a DTx company in the eye health space, has brought on ophthalmology and neuroscience expert Dirk Sauer , a veteran of Novartis Pharma, to advise the company as it continues to develop MyopiaX, a digital therapeutic for childhood myopia control. AI and robotics hires. McKinnell, Jr. to support the company’s growth.

Behavioural Health 52

Behavioural Health Reagent Gene Therapy Production 52

Roots Analysis

FEBRUARY 21, 2022

Since the introduction of a gene sequencing method by Frederick Sanger in 1977, the field of genomic data collection and analysis has evolved significantly. Advancement in DNA sequencing technologies have resulted in noteworthy developments in various healthcare-related research fields, such as diagnostics and personalized medicine.

Marketing 52

Marketing Gene Sequencing DNA Genome 52

Drug Discovery World

MAY 7, 2024

Ultimately, we owe it to patients to work together and come up with new and innovative manufacturing as well as process development approaches to accelerate the development and achieve speed to clinic. RA: In recent years, what improvements have we seen to cell-line engineering for antibodies?

Antibody 59

Antibody Production Manufacturing Engineer 59

Roots Analysis

FEBRUARY 23, 2022

NGS has emerged as an evolutionary technology in modern biotechnology and healthcare research, enabling researchers to develop a better understanding of the cause and consequences of disease. Next Generation Sequencing (NGS) Library Preparation Kits. Strong Intellectual Property Portfolio.

Genetics 52

Genetics DNA RNA Reagent 52

The Pharma Data

OCTOBER 14, 2020

Bio-Techne’s Woburn facility produces Cloudz Cell Activation Kits, a magnetic-free bead-based technology for the robust and reliable expansion of immune cells, including T cells and NK cells, representing a pivotal component of the cell and gene therapy workflow. ” About Bio-Techne Corporation (NASDAQ: TECH).

Manufacturing 40

Manufacturing Reagent Gene Therapy Protein 40

Drug Discovery World

OCTOBER 12, 2022

Professor Michael Butler, head of the National Institute for Bioprocessing Research and Training (NIBRT) Cell Technology Group (CTG), explains that the characterisation and analysis of glycans is important for the biopharma sector as it can help in the development of therapeutic agents such as monoclonal antibodies and other recombinant proteins.

Protein 52

Protein Gene Therapy Antibody Production 52

Drug Discovery World

JUNE 14, 2023

BCA members also operate the BCA Advanced Therapies Network which is a diverse, fully integrated portfolio of blood, cell, gene and tissue materials that support the development and delivery of advanced therapies. BCA and its members are developing innovative ways to attract younger donors through the use of technology.

Manufacturing 52

Manufacturing Production Gene Therapy Development 52

Drug Discovery World

DECEMBER 15, 2022

Possible solutions: A new generation of gene editing tools is being developed to avoid double stranded breaks altogether and to be potentially less destructive than traditional nuclease systems. Recent advances in gene editing technologies are extremely encouraging, with simple gene modifications becoming routine in animal models.

Gene Editing 52

Gene Editing Gene In-Vivo Genome 52

Drug Discovery World

JULY 18, 2023

Since its discovery in 2012, CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology has revolutionised the biomedicine and cell and gene therapy fields, providing a versatile tool for precise and efficient genome editing. CRISPR diagnostics have successfully detected various pathogens, including RNA viruses (eg.

DNA 98

DNA Genome Genomics RNA 98

Drug Discovery World

OCTOBER 13, 2022

There was a selection of the technologies we will present including cell-based assays, ion indicator dyes, inhibitors, pharmacokinetic assays, bioisimilars, assay development antibodies, conjugation particles and other reagents for your drug discovery and development pipeline. .

Drugs 52

Drugs In-Vivo In-Vitro Biobanking 52

Drug Discovery World

FEBRUARY 27, 2023

By focusing on workflow simplification and expanded assay capabilities in a state-of-the-art microplate reader, complemented by our optimised reagent technologies, our team has created an all-around high-performing system built for today and the future.” The launch follows the FDA Modernisation Act 2.0

Drugs 52

Drugs Life Science Protein Scientist 52